Physician profile
Andrea Roche
NPI 1477558849
$1,332.93
in general payments reported to CMS, 2019-2025
23 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $173 · 2021: $66.01 · 2022: $27.74 · 2023: $314 · 2024: $178 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $215.02 | 2019-2025 | |
| Astellas Pharma US INC | $185.21 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $174.06 | 2022-2025 | |
| Abbvie INC. | $148.35 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Biogen, INC. | $96.34 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $73.29 | 2020-2024 | Phexxi |
| Organon LLC | $64.88 | 2023-2025 | Nexplanon |
| Avion Pharmaceuticals | $60.06 | 2019-2020 | |
| Exeltis, USA INC. | $48.52 | 2020-2024 | Slynd |
| Pfizer INC. | $45.72 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $31.34 | 2019-2020 | |
| Duchesnay USA Incorporated | $27.69 | 2019 | |
| Roche Diagnostics Corporation | $23.46 | 2019 | |
| Mylan Pharmaceuticals INC. | $22.54 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $20.65 | 2024 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.22 | 2023 | Cologuard Collection Kit |
| Covidien LP | $15.52 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.04 | 2019 | |
| Hologic Sales and Service, LLC | $13.15 | 2024 | Myosure Tissue Removal Device, Acessa Provu System |
| Amag Pharmaceuticals, INC. | $12.47 | 2019 | |
| Allergan, INC. | $11.91 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.49 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Roche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.